CABA Cabaletta Bio, Inc: רווח למניה בשנים עשר החודשים האחרונים

Cabaletta Bio, Inc. (CABA) is developing advanced targeted cell therapy methods in the US to combat autoimmune malfunctions. This daily chart from GURU.Markets illustrates the rolling 12-month net income per share, where the -1.43 level serves as a critical benchmark. Cabaletta Bio, Inc. (CABA) focuses on curing lupus and pemphigus via B-cells, with the results of Phase I and II CAR-T therapy trials poised to be the immediate growth drivers.

To assess long-term risks, an investor analyzes EPS TTM as the ratio of total annual net income to the number of shares, which allows them to filter out noise and identify the actual efficiency of capital management. This daily price chart of net income per share over 12 months reflects the financial stability of Cabaletta Bio, Inc. (CABA) during the costly clinical trials of the CABA-201 platform and its expansion into the immunotherapy market.